<?xml version='1.0' encoding='utf-8'?>
<document id="28263465"><sentence text="Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications." /><sentence text="There are many factors that can affect the pharmacokinetics (PK) of drugs" /><sentence text=" Pathophysiological changes from disease states can alter the mechanisms that control the PK of antiretrovirals (ARVs), direct-acting antivirals (DAAs), and addiction treatment medications" /><sentence text=" Drug-drug interaction pathways of certain ARVs and DAAs can be very complex, with agents being substrates, inhibitors, or inducers of multiple metabolic and transporter pathways" /><sentence text=" Buprenorphine and methadone may be used in HIV- and hepatitis C virus (HCV)-infected patients and may also be affected by drug interactions"><entity charOffset="1-14" id="DDI-PubMed.28263465.s5.e0" text="Buprenorphine" /><entity charOffset="19-28" id="DDI-PubMed.28263465.s5.e1" text="methadone" /><pair ddi="false" e1="DDI-PubMed.28263465.s5.e0" e2="DDI-PubMed.28263465.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28263465.s5.e0" e2="DDI-PubMed.28263465.s5.e1" /></sentence><sentence text=" Current research is focused on novel PK analyses, which aim to describe the PK of agents within organs that host the infection of interest, such as within hepatocytes during treatment for HCV" /><sentence text=" Modeling techniques allow for the prediction of drug PK in specific organs and the plasma compartment" /><sentence text=" This review will provide a summary of these areas while exploring PK considerations for ARVs, DAAs, and addiction treatment medications" /><sentence text="" /></document>